RE:RE:RE:Why would anyoneJust seems like a very steep premium for SONA a company with no real track record.
I am a VST shareholder and even if both companies produce marketable tests I see more value here, especially at current prices.
I will continue to hold as infection rates are begining their rise again and companies like this should come back onto centre stage
GLTA